Adding chemotherapy when first treatment response is limited
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether adding a chemotherapy drug (docetaxel) to your current treatment (apalutamide) can help control prostate cancer that has spread and hasn't responded as well as hoped to apalutamide alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man at least 18 years old.
- You have prostate cancer that has spread to other parts of the body (metastatic) and is still hormone-sensitive.
- You have been taking apalutamide for about 6 to 7 months, but your PSA did not drop low enough (still above 0.2 ng/mL or did not drop by 90% or more).
- You have not had chemotherapy or certain other prostate cancer treatments before starting this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well men with prostate cancer that has spread and is still hormone-sensitive stick to taking the drug apalutamide. It aims to understand real-world use and quality of life.
This trial is for men with metastatic prostate cancer that has already spread beyond the pelvis. It tests whether adding a chemotherapy drug (docetaxel) to the usual hormone therapy plus apalutamide can help control the cancer better than hormone therapy alone.
This trial tests if adding docetaxel chemotherapy helps men whose PSA hasn't dropped enough after at least 6 months of standard hormone therapy (ADT) plus an ARPI pill (like abiraterone or enzalutamide) for metastatic prostate cancer that still responds to hormones.
This trial looks at combining hormone therapy with either chemotherapy (docetaxel), a targeted pill (like abiraterone or enzalutamide), or radiation to the prostate tumor for men whose prostate cancer has spread but is still sensitive to hormones. The goal is to see which approach works best for controlling the cancer.
This trial tests whether adding surgery to remove the prostate and radiation to visible cancer spots, along with the usual hormone therapy, can help men with newly diagnosed prostate cancer that has spread. It aims to see if this more intensive approach can improve outcomes.
This early-phase trial tests whether adding apantamide to hormone therapy (and possibly adding docetaxel chemotherapy) works better and is safe for men with high-volume spread of prostate cancer. It’s designed for people who have recently started hormone therapy and haven’t shown clear disease worsening yet.
Hear when a new Metastatic Hormone-sensitive Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.